CENTEXT CENTEXT NSE
Company Profile ↓Company Overview
CENTEXT (CENTEXT) is a publicly traded company listed on NSE with a market capitalization of ₹152.00 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Return on capital employed stands at 29.0%.
Net profit has compounded at 22.5% per year over the last five years.
Trades at an undemanding P/E of 13.9.
Recent Developments
- Mar 2026 Revenue of ₹478.56 Cr (+11.0% YoY); net profit ₹10.97 Cr.
- Trailing 12 Months Year-on-year growth — revenue +11.0%, earnings +10.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 22.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.76% |
| 1 Year: | 10.97% |
Compounded Profit Growth
| 5 Years: | 22.48% |
| 1 Year: | 10.36% |
Stock Price Performance
| 1 Year: | -13.44% |
| 6 Months: | -18.52% |
| 3 Months: | -8.35% |
| 1 Month: | -6.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 29.0%.
- Profit CAGR of 22.5% over 5 years.
CONS
- Trading 44.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 119.79 Cr | 104.15 Cr | 109.66 Cr | 122.53 Cr | 142.22 Cr |
| Cost of Revenue | - | 90.96 Cr | 78.36 Cr | 84.44 Cr | 95.46 Cr | 114.17 Cr |
| Gross Profit | - | 28.83 Cr | 25.79 Cr | 25.22 Cr | 27.07 Cr | 28.05 Cr |
| Operating Expenses | - | 23.08 Cr | 20.04 Cr | 18.66 Cr | 20.10 Cr | 21.44 Cr |
| Operating Income | - | 5.75 Cr | 5.75 Cr | 6.56 Cr | 6.97 Cr | 6.61 Cr |
| EBITDA | - | 6.95 Cr | 7.03 Cr | 7.70 Cr | 8.48 Cr | 8.49 Cr |
| Interest Expense | - | 2.91 Cr | 2.67 Cr | 3.02 Cr | 3.50 Cr | 1.54 Cr |
| Pretax Income | - | 3.28 Cr | 3.14 Cr | 3.57 Cr | 3.79 Cr | 4.61 Cr |
| Tax Provision | - | 61.00 L | 78.00 L | 81.00 L | 89.00 L | 1.66 Cr |
| Net Income | 2.45 Cr | 2.67 Cr | 2.36 Cr | 2.76 Cr | 2.90 Cr | 2.95 Cr |
| Diluted EPS | - | 0.33 | 0.30 | 0.35 | 0.36 | 0.37 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 372.01 Cr | 375.10 Cr | 431.25 Cr | 478.56 Cr |
| Cost of Revenue | - | 294.38 Cr | 293.10 Cr | 332.12 Cr | 372.43 Cr |
| Gross Profit | - | 77.63 Cr | 82.00 Cr | 99.13 Cr | 106.13 Cr |
| Operating Expenses | - | 58.96 Cr | 62.62 Cr | 76.65 Cr | 80.24 Cr |
| Operating Income | - | 18.67 Cr | 19.38 Cr | 22.48 Cr | 25.89 Cr |
| EBITDA | - | 18.98 Cr | 21.50 Cr | 26.61 Cr | 31.70 Cr |
| Interest Expense | - | 7.29 Cr | 7.26 Cr | 10.37 Cr | 10.73 Cr |
| Pretax Income | - | 8.64 Cr | 10.89 Cr | 12.81 Cr | 15.11 Cr |
| Tax Provision | - | 2.67 Cr | 3.44 Cr | 2.87 Cr | 4.14 Cr |
| Net Income | - | 5.97 Cr | 7.45 Cr | 9.94 Cr | 10.97 Cr |
| Diluted EPS | - | 0.75 | 0.93 | 1.24 | 1.37 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 132.90 Cr | 159.25 Cr | 170.83 Cr | 187.46 Cr |
| Current Assets | - | 100.82 Cr | 116.95 Cr | 113.29 Cr | 133.49 Cr |
| Cash & Equivalents | - | 8.06 Cr | 10.56 Cr | 10.06 Cr | 28.00 L |
| Inventory | - | 32.79 Cr | 39.63 Cr | 40.56 Cr | 68.16 Cr |
| Receivables | - | 34.19 Cr | 35.35 Cr | 35.44 Cr | 35.62 Cr |
| Total Liabilities | - | 67.75 Cr | 86.20 Cr | 87.86 Cr | 104.56 Cr |
| Current Liabilities | - | 59.91 Cr | 81.08 Cr | 83.10 Cr | 98.30 Cr |
| Long Term Debt | - | 7.11 Cr | 4.30 Cr | 1.86 Cr | 21.00 L |
| Total Debt | - | 47.73 Cr | 48.46 Cr | 51.92 Cr | 62.14 Cr |
| Total Equity | - | 65.15 Cr | 73.05 Cr | 82.97 Cr | 82.90 Cr |
| Shares Outstanding | - | 8.00 Cr | 8.00 Cr | 8.00 Cr | 8.00 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 13.70 Cr | 11.38 Cr | 13.31 Cr | 4.05 Cr |
| Investing Cash Flow | - | -52.00 L | -4.97 Cr | -6.16 Cr | -16.90 Cr |
| Financing Cash Flow | - | -5.39 Cr | -6.52 Cr | -7.65 Cr | 3.07 Cr |
| Capital Expenditure | - | -95.00 L | -5.39 Cr | -6.56 Cr | -17.55 Cr |
| Free Cash Flow | - | 12.75 Cr | 5.99 Cr | 6.75 Cr | -13.50 Cr |
| Net Change in Cash | - | 7.79 Cr | -11.00 L | -50.00 L | -9.78 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 20.9% | 21.9% | 23.0% | 22.2% |
| Operating Margin % | - | 5.0% | 5.2% | 5.2% | 5.4% |
| Net Margin % | - | 1.6% | 2.0% | 2.3% | 2.3% |
| ROE % | - | 9.2% | 10.2% | 12.0% | 13.2% |
| ROCE % | - | 25.6% | 24.8% | 25.6% | 29.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CENTEXT
Context Therapeutics Decline Means Insider Profits Down To US$237k - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOdmp4M05uU0psVEw5eVFwNDlseHNPYVpPNHJiRGFBOW55dVlMbk8xQnZCMHpCQ0V6YXUyNGtfUnFucjhTLUFGNmNidVpTbXFoN2dsOFAyQkJNTzZYMzdncjUtY2pIUWZONkZXQ3cyZkdmZEh6eVlZeUdqUWdJMFFSdlJQS2NVcWl4MGhmVE…
Declining Stock and Decent Financials: Is The Market Wrong About Century Extrusions Limited (NSE:CENTEXT)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQNGhhV1JLZXA3YTgxYlZ3dlVEM1dJSzFMZmNhZjU4MWN6WC1sQklPazlEaXBiVWFqb1FtUmRmazlRX0JDUzdFNVNYUUNYaFBCdGlYa0dRakk1TlBuQktNb0ZLMTI2NDJfcVhKbDBacWprTTBRRE5SRDdqUWlSN2doYkhSbUpmVk5rWndXZU…
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - Stocktwits
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNVGpzZVFUakE3bWpCc296LUxic25QcE83Qm5KUmN2Q0xpbmlDYnF1MF9Ra3o2THF4V2VaLWFvd1NzRUhjV2tUWUpoS1dkUWdwVzQ4amZIdndnd2k5TFBCT2sxeWxjQ2tYSnlSNEU3YzB2MkpCVklneEZ3aHlYdmtkYTFUMmhieWdRLVgzbU…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBEaVZwX1RNeENlWXFWTWlPZzFzS2VWbUp0RWNsOU55S2hzdWc1Qk9tTHhiZ0VwRXA0WEx2eVE1MUx0X244aXU3VmNHWHo2ZXl5?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
CNTX Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBDMHVCU1B2eTdFUUVzWU1KUUl0TlRBMWVhcE42ODBBQ0EwQ0pFeDFFYjJiaFBNcEhzSi1JZFVPRFc1bFpIcllCcFpGMlI4aGIwUmQtNG1abFJhRkVjWnB3?oc=5" target="_blank">CNTX Stock Price, Quote & Chart</a>&nbs…
CENTEXT Stock Price and Chart — NSE:CENTEXT - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9CSGtxdHlPam50RnJzVVlqYnBjUUotX05iYUhERXdET1BwUWw4NGFLc0E2eENCbVFKclVDbWVmM1NHVVpHejJQOTEycUhaNFhiNG9YdWNnUllVcGRk?oc=5" target="_blank">CENTEXT Stock Price and Chart — NSE:CENTEXT…
CENTEXT — Frequently Asked Questions
What is the current share price of CENTEXT?
As of 2026-07-15 09:52 IST, CENTEXT trades at ₹19.00 on NSE. Its 52-week range is ₹16.52 to ₹33.95.
What is the market capitalisation of CENTEXT?
CENTEXT has a market capitalisation of ₹152.00 Cr on NSE.
What is the P/E ratio of CENTEXT?
CENTEXT trades at a trailing price-to-earnings (P/E) ratio of 13.87. Its price-to-book (P/B) ratio is 1.84.
What is the return on equity (ROE) of CENTEXT?
CENTEXT has a return on equity (ROE) of 13.23%. Its return on capital employed (ROCE) is 29.04%.
Is CENTEXT a good stock to buy?
This page provides a data-driven analysis of CENTEXT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.